Company news
SeaStar Medical Holding Corporation news in 2023
SeaStar Medical Holding Corporation's news releases, calls and decks from 2023, newest first.
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
December 27, 2023
SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts
December 12, 2023
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 13, 2023
FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome
October 17, 2023
SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
October 2, 2023
FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for Cardiorenal Syndrome
September 28, 2023
SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 13, 2023
First Patient Enrolled in SeaStar Medical’s Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
June 19, 2023
SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business Update
May 14, 2023
SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device
May 8, 2023
SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury
April 18, 2023
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
March 29, 2023
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement
March 15, 2023
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
February 14, 2023
SeaStar Medical to Hold Business Update Conference Call on February 15, 2023
February 13, 2023
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
February 8, 2023
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients
January 8, 2023
Decks in 2023
- Investor Presentation (February 2023)
Investor deck · 28 slides · Feb 15, 2023